A regulation that came into effect in Germany in early 2011 now stipulates that the added benefit of most medications containing new active ingredients be assessed as soon as they enter the market. Manufacturers initially set the prices for their new medications, but afterwards prices are based on the results of this assessment, called an “early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG).”

When a medication is launched, the manufacturer is required to submit a dossier to the German Federal Joint Committee (G-BA) for early benefit assessment. This dossier must contain the results of all relevant studies on the new drug.

The Institute for Quality and Efficiency in Health Care (IQWiG, Germany) assesses this dossier on behalf of G-BA. Within three months, IQWiG issues a review evaluating the advantages and disadvantages of the new drug in comparison with an appropriate comparator treatment. G-BA and IQWiG both publish the final review.

You can find these drugs in the following table. An alphabetical list is available here.

Digestive system and metabolism

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Albiglutide Eperzan Type 2 diabetes
Asfotase alfa Strensiq Hypophosphatasia
Canagliflozin Invokana Type 2 diabetes
Dapagliflozin EU: Forxiga
U.S.: Farxiga
Type 2 diabetes
Dapagliflozin / metformin as a fixed-dose combination Xigduo Type 2 diabetes
Dulaglutide Trulicity Type 2 diabetes
Empagliflozin Jardiance Type 2 diabetes
Empagliflozin / linagliptin as a fixed-dose combination Glyxambi Type 2 diabetes
Empagliflozin / metformin as a fixed-dose combination Synjardy Type 2 diabetes
Ertugliflozin / sitagliptin as a fixed-dose combination Steglujan Type 2 diabetes
Glycopyrronium bromide Sialanar Chronic pathological drooling
Insulin degludec Tresiba Type 1 diabetes and type 2 diabetes
Insulin degludec Tresiba Diabetes in teenagers and children
Insulin degludec Tresiba Type 2 diabetes
Insulin degludec / liraglutide as a fixed-dose combination Xultophy Type 2 diabetes
Insulin glargine / lixisenatide as a fixed-dose combination Suliqua Type 2 diabetes
Naldemedine Rizmoic Opioid-induced constipation
Netupitant / palonosetron as a fixed-dose combination Akynzeo Chemotherapy-related nausea and vomiting
Rolapitant EU: Varuby
U.S.: Varubi
Cancer-related nausea and vomiting
Saxagliptin Onglyza Type 2 diabetes
Saxagliptin / metformin as a fixed-dose combination Komboglyze Type 2 diabetes
Semaglutide Ozempic Type 2 diabetes
Sitagliptin Januvia, Xelevia Type 2 diabetes
Sitagliptin / metformin as a fixed-dose combination Janumet, Velmetia Type 2 diabetes
Vildagliptin Galvus, Jalra Type 2 diabetes

Blood and blood production

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Apixaban Eliquis Deep vein thrombosis and pulmonary embolism
Damoctocog alfa pegol Jivi Hemophilia A
Edoxaban Lixiana Atrial fibrillation
Edoxaban Lixiana Deep vein thrombosis (DVT) and pulmonary embolism
Emicizumab Hemlibra Hemophilia A
Lonoctocog alfa Afstyla Hemophilia A
Nonacog beta pegol Refixia Hemophilia B
Rurioctocog alfa pegol Adynovi Hemophilia A
Selexipag Uptravi Pulmonary arterial hypertension
Simoctocog alfa Nuwiq Hemophilia A
Turoctocog alfa pegol Esperoct Hemophilia A

Heart and circulation

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Alirocumab Praluent Hypercholesterolemia and mixed dyslipidemia
Evolocumab Repatha Hypercholesterolemia and mixed dyslipidemia
Lomitapide Lojuxta Familial hypercholesterolemia
Macitentan Opsumit Pulmonary arterial hypertension
Propranolol Hemangiol Hemangioma in infants


Pulmonary hypertension


Pulmonary arterial hypertension

EU: Brilique
U.S.: Brilinta

High risk of a stroke or heart attack

Skin and hair

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Dupilumab Dupixent Eczema
Ingenol mebutate Picato Actinic keratosis

Sexual organs and urinary tract

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Mirabegron Betmiga Overactive bladder

EU: Senshio
U.S.: Osphena/Ophena

Vaginal atrophy


Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Etelcalcetide Parsabiv Hyperparathyroidism
Hydrocortisone Alkindi Adrenal insufficiency


Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Bezlotoxumab Zinplava Costridium difficile infections
Bictegravir / emtricitabine / tenofovir alafenamide as a fixed-dose combination Biktarvy HIV infection
Daclatasvir Daklinza Hepatitis C
Darunavir combination Symtuza HIV infection
Dasabuvir Exviera Chronic hepatitis C
Dolutegravir Tivicay HIV infection
Dolutegravir (combined with abacavir and lamivudine) Triumeq HIV infection
Dolutegravir / rilpivirine as a fixed-dose combination Juluca HIV infection
Doravirine Pifeltro HIV infection
Doravirine / lamivudine / tenofovir disoproxil fumarate as a fixed-dose combination Delstrigo HIV infection
Elbasvir / grazoprevir Zepatier Hepatitis C
Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide as a fixed-dose combination Genvoya HIV infection
Elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil as a fixed-dose combination Stribild HIV infection in teenagers
Emtricitabine / tenofovir alafenamide as a fixed-dose combination Descovy HIV infection
Emtricitabine / rilpivirine / tenofovir alafenamide as a fixed-dose combination Odefsey HIV infection
Glecaprevir / pibrentasvir as a fixed-dose combination Maviret Chronic hepatitis C
Ledipasvir (combined with sofosbuvir) Harvoni Chronic hepatitis C
Ledipasvir / sofosbuvir as a fixed-dose combination Harvoni Chronic hepatitis C in teenagers
Ombitasvir / paritaprevir / ritonavir as a fixed-dose combination Viekirax Chronic hepatitis C
Ravulizumab Ultomiris Paroxysmal nocturnal hemoglobinuria
Rilpivirine Edurant HIV infection
Simeprevir Olysio Chronic hepatitis C
Sofosbuvir Sovaldi Chronic hepatitis C
Sofosbuvir / velpatasvir as a fixed-dose combination Epclusa Chronic hepatitis C
Sofosbuvir / velpatasvir / voxilaprevir as a fixed-dose combination Vosevi Chronic hepatitis C
Tenofovir alafenamide Vemlidy Chronic hepatitis B

Cancer and the immune system

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Abiraterone acetate Zytiga Metastatic prostate cancer
Abemaciclib and aromatase inhibitor

EU: Verzenios
U.S.: Verzenio

Advanced breast cancer
Abemaciclib and fulvestrant

EU: Verzenios
U.S.: Verzenio

Advanced breast cancer
Afatinib Giotrif Advanced lung cancer
Afatinib Giotrif Advanced squamous cell lung cancer
Alectinib Alecensa Advanced lung cancer
Apalutamide Erleada

Prostate cancer

Apalutamide Erleada Metastatic prostate cancer
Apremilast Otezla Behçet's disease
Apremilast Otezla Psoriasis
Atezolizumab Tecentriq Advanced lung cancer
Atezolizumab Tecentriq Bladder cancer (urothelial carcinoma)
Avelumab Bavencio Advanced renal cell cancer
Axitinib Inlyta Advanced renal cell cancer
Baricitinib Olumiant Rheumatoid arthritis
Belatacept Nulojix Following a kidney transplant
Belimumab Benlysta Systemic lupus erythematosus in children and teenagers
Binimetinib and encorafenib (combination) Mektovi / Braftovi Advanced melanoma
Brigatinib Alunbrig Advanced non-small-cell lung cancer
Bosutinib Bosulif Chronic myeloid leukemia
Cabozantinib Cabometyx Advanced hepatocellular carcinoma
Cabozantinib Cabometyx Avanced renal cell cancer
Carfilzomib Kyprolis Multiple myeloma
Cemiplimab Libtayo Advanced non-melanoma skin cancer
Ceritinib Zykadia Advanced lung cancer
Cladribine Mavenclad Multiple sclerosis
Cobimetinib Cotellic Melanoma
Crizotinib Xalkori Advanced lung cancer
Dabrafenib and trametinib (combination) Tafinlar / Mekinist Melanoma
Dacomitinib Vizimpro Advanced lung cancer
Daratumumab Darzalex Multiple myeloma
Darolutamide Nubeqa Prostate cancer
Dolutegravir / lamivudine Dovato HIV
Durvalumab Imfinzi Advanced lung cancer
Elotuzumab Empliciti Multiple myeloma
Enzalutamide Xtandi Metastatic prostate cancer
Eribulin Halaven Liposarcoma
Fingolimod Gilenya Multiple sclerosis
Guselkumab Tremfya Psoriasis
Ibrutinib Imbruvica Chronic lymphocytic leukemia
Ibrutinib Imbruvica Mantle cell lymphoma
Ibrutinib Imbruvica

Waldenström's macroglobulinemia

Idelalisib Zydelig Chronic lymphocytic leukemia
Idelalisib Zydelig Non-Hodgkin's lymphoma


Ipilimumab combined with nivolumab

Yervoy / Opdivo

Advanced renal cell cancer




Advanced tumor

EU: Kisplyx
U.S.: Lenvima

Advanced renal cell cancer


Advanced thyroid cancer
Lenvatinib Lenvima Hepatocellular carcinoma (liver cancer)

EU: Lorviqua
U.S.: Lorbrena

Advanced lung cancer
Necitumumab Portrazza Advanced lung cancer
Neratinib Nerlynx Breast cancer
Nintedanib Ofev Idiopathic pulmonary fibrosis
Nintedanib Vargatef Advanced lung cancer
Niraparib Zejula Ovarian cancer
Nivolumab Opdivo Advanced non-small cell lung cancer
Nivolumab Opdivo Advanced renal cell cancer
Nivolumab Opdivo Head and neck cancer
Nivolumab Opdivo Hodgkin's lymphoma
Nivolumab Opdivo Melanoma
Nivolumab Opdivo Advanced bladder cancer (urothelial carcinoma)
Ocrelizumab Ocrevus Multiple sclerosis
Olaparib Lynparza Advanced breast cancer
Olaparib Lynparza Ovarian cancer
Osimertinib Tagrisso Advanced lung cancer with T790M mutation
Osimertinib Tagrisso Advanced lung cancer with activating EGFR mutations
Palbociclib Ibrance Advanced breast cancer
Pembrolizumab Keytruda Advanced lung cancer
Pembrolizumab in combination with chemotherapy Keytruda Advanced lung cancer
Pembrolizumab Keytruda Advanced bladder cancer (urothelial carcinoma)
Pembrolizumab Keytruda Advanced renal cell carcinoma
Pembrolizumab Keytruda Head and neck cancer
Pembrolizumab Keytruda Hodgkin's lymphoma
Pembrolizumab Keytruda Melanoma
Pertuzumab Perjeta Breast cancer

EU: Imnovid
U.S.: Pomalyst

Multiple myeloma
Radium-223 dichloride Xofigo Advanced prostate cancer
Ramucirumab Cyramza Bowel cancer
Ramucirumab Cyramza Advanced liver cancer
Ramucirumab Cyramza Advanced lung cancer
Ramucirumab Cyramza Advanced stomach cancer
Ribociclib Kisqali Advanced breast cancer
Risankizumab Skyrizi Psoriasis
Ropeginterferon alfa-2b Besremi Polycythemia vera
Rucaparib Rubraca Advanced ovarian cancer
Ruxolitinib Jakavi Myelofibrosis
Ruxolitinib Jakavi Polycythemia vera
Sarilumab Kevzara Rheumatoid arthritis
Secukinumab Cosentyx Psoriasis
Secukinumab Cosentyx Ankylosing spondylitis (Bekhtherev's disease)
Sipuleucel-T Provenge Metastatic prostate cancer
Sonidegib Odomzo Non-melanoma skin cancer
Talimogen laherparepvec Imlygic Melanoma
Tildrakizumab EU: Ilumetri
U.S.: Ilumya
Tivozanib Fotivda Advanced renal cell cancer
Trametinib / dabrafenib Mekinist / Tafinlar Advanced lung cancer
Tofacitinib Xeljanz Psoriatic arthritis
Tofacitinib Xeljanz Rheumatoid arthritis
Tofacitinib Xeljanz Ulcerative colitis
Trifluridine / tipiracil Lonsurf Advanced gastric cancer
Trifluridine / tipiracil Lonsurf Metastatic colorectal cancer
Upadacitinib Rinvoq Rheumatoid arthritis
Vandetanib Caprelsa Aggressive thyroid cancer
Vedolizumab Entyvio Crohn's disease
Venetoclax EU: Venclyxto
U.S.: Venclexta
Chronic lymphocytic leukemia (CLL)
Vismodegib Erivedge Basal cell carcinoma

Muscles and skeletal system

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Collagenase extracted from Clostridium histolyticum Xiapex Dupuytren’s contracture
Romosozumab Evenity Osteoporosis

Brain and nervous system

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Brivaracetam Briviact Epilepsy
Cannabis sativa Sativex Spasticity in multiple sclerosis
Cariprazin Reagila Schizophrenia
Dimethyl fumarate Skilarence Psoriasis
Dimethyl fumarate Tecfidera Multiple sclerosis
Erenumab Aimovig

Prevention of migraine

Fremanezumab Ajovy Migraine
Galcanezumab Emgality Prevention of migraine
Lisdexamfetamine EU: Elvanse / Elvanse Adult
U.S.: Vyvanse
Lurasidone Latuda Schizophrenia
Melatonin Slenyto Insomnia
Nalmefene Selincro Alcohol dependency
Opicapone Ongentys Parkinson's disease
Perampanel Fycompa Epilepsy
Safinamide Xadago Parkinson's disease
Siponimod Mayzent Multiple sclerosis
Solriamfetol Sunosi Narcolepsy
Vortioxetine Brintellix Depression

Lungs and breathing

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Aclidinium bromide / formoterol as a fixed-dose combination Duaklir Genuair, Brimica Genuair Chronic obstructive pulmonary disease (COPD)
Benralizumab Fasenra Severe asthma
Dupilumab Dupixent Chronic rhinosinusitis with nasal polyps
Dupilumab Dupixent Severe asthma
Fluticasone furoate / umeclidinium / vilanterol as a fixed-dose combination Trelegy ellipta Chronic obstructive pulmonary disease (COPD)
Indacaterol and glycopyrronium Ultibro Breezhaler, Xoterna Breezhaler Chronic obstructive pulmonary disease (COPD)
Ivacaftor Kalydeco Cystic fibrosis
Ivacaftor and the fixed-dose combination tezacaftor/ivacaftor Kalydeco/Symkevi Cystic fibrosis
Lumacaftor / ivacaftor as a fixed-dose combination Orkambi Cystic fibrosis
Mepolizumab Nucala Severe asthma
Reslizumab EU: Cinqaero
U.S.: Cinqair
Severe asthma
Umeclidinium Incruse Chronic obstructive pulmonary disease (COPD)
Umeclidinium and vilanterol Anoro Chronic obstructive pulmonary disease (COPD)

Sensory organs

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Aflibercept Eylea Age-related macular degeneration
Aflibercept Eylea Diabetic macular edema
Aflibercept Eylea

Macular edema following retinal vein occlusion

Aflibercept Eylea

Myopic choroidal neovascularization

Ocriplasmin Jetrea Vitreomacular traction
Tafluprost / Timolol Taptiqom Glaucoma


Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Andexanet alfa Ondexxya (EU), Andexxa (U.S.) Major bleeding
Patiromer Veltassa Hyperkalemia
Sucroferric oxyhydroxide Velphoro Chronic renal insufficiency